J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology

 J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology

J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology

Shots:

  • Nanjing has received $350M from J&J for the global co-development and Commercialization rights for gene therapy for myeloma under development with Llama DNA. J&J is trying to enter CAR-T therapy market by making this deal
  • The U.S. FDA has approved the testing of investigational drug on the US population in May 2018, making it the first gene therapy developed by china to receive an approval. Nanjing plans to initiate the US trial this from Aug 2018
  • Legend a unit of GenScript Biotech, a firm that designs artificial genes for drug companies, plans to file it next year with China’s FDA for approval as first Chinese CAR-T treatment 

Click here to read full press release/ article | Ref: Morning Star  | Image: Market Exclusive

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post